MENOPAUSE, MEDROXYPROGESTERONE AND BREATHING DURING SLEEP
MENOPAUSE, MEDROXYPROGESTERONE AND BREATHING DURING SLEEP
复制标题
DOI：
10.1016/0002-9343(81)90572-6
复制
发表时间：
1981-01-01
影响因子：
5.9
通讯作者：
CANTOR, B
中科院分区：
文献类型：
--
作者：
BLOCK, AJ;WYNNE, JW;CANTOR, B
对绝经后妇女[21]进行睡眠呼吸紊乱和夜间氧气减饱和监测，以评估孕激素对这些睡眠事件发生的影响。大约1个月。在一项随机双盲对照研究中，11名受试者每天服用30毫克甲羟孕酮(MPG)，10名受试者接受安慰剂片剂。分别于治疗前1晚和治疗后1晚监测呼吸、血氧饱和度和脑电图。与绝经前女性呼吸紊乱和饱和度降低的低发生率相比，71%的绝经后女性发生了此类事件。在安慰剂治疗组中，所有测量的睡眠和呼吸变量在两个晚上都是相同的，这表明一个晚上的睡眠监测结果可能代表其他晚上的睡眠。虽然一些受试者在服用MPG后似乎有所改善，但只有呼吸暂停的最大持续时间在第二天晚上显著减少(P<；0.03)。
Postmenopausal women [21] were monitored for sleep-disordered breathing and nocturnal O2 desaturation to evaluate the contribution of progestational hormones to the occurrence of these sleep events. For approximately 1 mo. 11 subjects received 30 mg of medroxyprogesterone (MPG) daily, and 10 received placebo tablets in a randomized, double-blind controlled study. Respiration, saturation and EEG were monitored during 1 night of sleep before and 1 night after therapy. Contrasted with the low incidence of disordered breathing and desaturation in premenopausal women, 71% of the postmenopausal women had such events. In the placebo-treated group, all measured variables of sleep and breathing were identical on the 2 nights, which suggested that the findings of a single night of sleep monitoring may be representative of other nights of sleep. Although several subjects appeared to show improvement with MPG, only the maximum duration of apnea was significantly reduced the 2nd night (P < 0.03).